BioSyent Stock

BioSyent EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of BioSyent (RX.V) as of Jul 31, 2026 is 15.53. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 19.38 — a change of -19.88% (lower).

EV/EBIT

15.53

YoY

-19.88%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of BioSyent is 2026 15.53 . EV/EBIT (Enterprise Value to EBIT) of BioSyent was 2025 19.38 . It decreases by -19.88% lower compared to the previous year.

The BioSyent EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
15.37 base
Jan 1, 2020
20.33 base
Jan 1, 2021
12.79 base
Jan 1, 2022
12.13 base
Jan 1, 2023
14.37 base
Jan 1, 2024
14.06 base
Jan 1, 2025
13.04 base
Jan 1, 2026 (e)
9.16 base
YEARPRICE-TO-EBIT
2026 est 9.16
2025 13.04
2024 14.06
2023 14.37
2022 12.13
2021 12.79
2020 20.33
2019 15.37
2018 17.07
2017 20.38
2016 20.19
2015 20.05
2014 40.98
2013 25.22
2012 9.40
2011 11.24
2010 12.54
2009 -0.04
2008 -0.01
2007 -
2006 -
Access this data via the Eulerpool API
Get Free API Key

BioSyent Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides BioSyent's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates BioSyent's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots BioSyent's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if BioSyent grows earnings faster than its peers.

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

EV/EBIT (Enterprise Value to EBIT) of BioSyent is 15.53 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — BioSyent

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — BioSyent